Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

Long-term results from the OLYMPIA open-label extension study show that nemolizumab (Nemluvio) provides durable efficacy and good tolerability for up to 3 years in patients with ...

Demonstrates Long-Term Disease Control In Prurigo Nodularis Up To Three Years - AETOS....(BUSINESS WIRE )--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study inv ...

Nemluvio demonstrated long-term improvements in itch intensity, skin lesions and quality of life The OLYMPIA LTE study was designed to assess the safety and efficacy of Nemluvio in patients with ...

The recent safety update led Kyowa Kirin and Amgen to conclude potential risks may outweigh benefits for patient populations.

Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. 1 Results ...

Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the discontinuation of all ongoing clinical trials for rocatinlimab, an ...

Galderma announces positive data from OLYMPIA open-label extension study of Nemluvio in moderate-to-severe prurigo nodularis: Zug, Switzerland Monday, March 2, 2026, 15:00 Hrs [IS ...

Kyowa Kirin announced it is discontinuing all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody, after a safety review identified “emerging concerns” of ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...